Brought to you by 
Forest gets exclusive US rights to Nycomed's Daxas
27 Oct 2020
Executive Summary
Forest Laboratories has licensed exclusive US marketing rights to fellow specialty drug company Nycomed's Daxas (roflumilast). Nycomed, which is developing the selective once-daily PDE4 enzyme inhibitor for symptomatic COPD, filed an NDA last month after completing four Phase III trials.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Forest gets exclusive US rights to Nycomed's Daxas
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice